Scopus BioPharma Inc. [NASDAQ: SCPS] gained 51.59% or 0.12 points to close at $0.37 with a heavy trading volume of 15922949 shares. The company report on October 18, 2022 that Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated.
Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million.
It opened the trading session at $0.3067, the shares rose to $0.51 and dropped to $0.26, the range by which the price of stock traded the whole day. The daily chart for SCPS points out that the company has recorded -39.31% loss over the past six months. However, it is still -76.19% lower than its most recent low trading price.
If we look at the average trading volume of 89.70K shares, SCPS reached to a volume of 15922949 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Scopus BioPharma Inc. [SCPS]:
The Benchmark Company have made an estimate for Scopus BioPharma Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on February 16, 2021.
Trading performance analysis for SCPS stock
Scopus BioPharma Inc. [SCPS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 48.62. With this latest performance, SCPS shares gained by 37.78% in over the last four-week period, additionally sinking by -39.31% over the last 6 months – not to mention a drop of -90.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SCPS stock in for the last two-week period is set at 67.34, with the RSI for the last a single of trading hit 74.93, and the three-weeks RSI is set at 61.33 for Scopus BioPharma Inc. [SCPS]. The present Moving Average for the last 50 days of trading for this stock 0.3172, while it was recorded at 0.2713 for the last single week of trading, and 0.5735 for the last 200 days.
Scopus BioPharma Inc. [SCPS]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -1,462.39, with Return on Assets sitting at -462.25.
Scopus BioPharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
An analysis of insider ownership at Scopus BioPharma Inc. [SCPS]
There are presently around $0 million, or 3.30% of SCPS stock, in the hands of institutional investors. The top three institutional holders of SCPS stocks are: GEODE CAPITAL MANAGEMENT, LLC with ownership of 217,078, which is approximately 6.513% of the company’s market cap and around 50.66% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 130,852 shares of the stock with an approximate value of $49000.0 in SCPS stocks shares; and M&R CAPITAL MANAGEMENT INC, currently with $29000.0 in SCPS stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Scopus BioPharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 6 institutional holders increased their position in Scopus BioPharma Inc. [NASDAQ:SCPS] by around 126,147 shares. Additionally, 7 investors decreased positions by around 449,028 shares, while 9 investors held positions by with 111,508 shares. The mentioned changes placed institutional holdings at 686,683 shares, according to the latest SEC report filing. SCPS stock had 2 new institutional investments in for a total of 75,567 shares, while 5 institutional investors sold positions of 104,236 shares during the same period.